HK1204474A1 - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders - Google Patents
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disordersInfo
- Publication number
- HK1204474A1 HK1204474A1 HK15105006.4A HK15105006A HK1204474A1 HK 1204474 A1 HK1204474 A1 HK 1204474A1 HK 15105006 A HK15105006 A HK 15105006A HK 1204474 A1 HK1204474 A1 HK 1204474A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bifluorodioxalane
- autoimmuneinflammation
- benzimidazole
- cancer
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| EP12174669 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1204474A1 true HK1204474A1 (en) | 2015-11-20 |
Family
ID=49782305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15105006.4A HK1204474A1 (en) | 2012-06-27 | 2015-05-26 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9580438B2 (ja) |
| EP (1) | EP2867237A1 (ja) |
| JP (2) | JP6272846B2 (ja) |
| KR (1) | KR102155559B1 (ja) |
| CN (1) | CN104540831B (ja) |
| AU (2) | AU2013283318B2 (ja) |
| BR (1) | BR112014032581A8 (ja) |
| CA (1) | CA2877589C (ja) |
| EA (1) | EA029718B1 (ja) |
| HK (1) | HK1204474A1 (ja) |
| IL (1) | IL236463A0 (ja) |
| IN (1) | IN2014MN02562A (ja) |
| MX (1) | MX350418B (ja) |
| MY (1) | MY167785A (ja) |
| NZ (1) | NZ702618A (ja) |
| SG (1) | SG11201408617PA (ja) |
| UA (1) | UA116541C2 (ja) |
| WO (1) | WO2014001464A1 (ja) |
| ZA (1) | ZA201409194B (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014MN02562A (ja) * | 2012-06-27 | 2015-07-24 | 4Sc Discovery Gmbh | |
| CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| PT3119762T (pt) | 2014-03-20 | 2021-08-31 | Capella Therapeutics Inc | Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro |
| ES2838573T3 (es) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| WO2017053537A1 (en) | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| IL295649A (en) * | 2016-04-07 | 2022-10-01 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides are useful as protein modulators |
| JP2021500394A (ja) | 2017-10-27 | 2021-01-07 | シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド | αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法 |
| US20220033418A1 (en) | 2018-09-13 | 2022-02-03 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN109020990A (zh) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| WO2021261601A1 (ja) | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| CN116942819A (zh) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| CA2458533C (en) | 2001-10-09 | 2011-01-04 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| EP2947073B1 (en) * | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| IN2014MN02562A (ja) * | 2012-06-27 | 2015-07-24 | 4Sc Discovery Gmbh |
-
2013
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/pt not_active Application Discontinuation
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/ja not_active Expired - Fee Related
- 2013-06-27 EA EA201500050A patent/EA029718B1/ru not_active IP Right Cessation
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
- 2013-06-27 US US14/411,795 patent/US9580438B2/en active Active
- 2013-06-27 UA UAA201500560A patent/UA116541C2/uk unknown
- 2013-06-27 MX MX2014015938A patent/MX350418B/es active IP Right Grant
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/ko active IP Right Grant
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/zh not_active Expired - Fee Related
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en active Application Filing
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2015
- 2015-05-26 HK HK15105006.4A patent/HK1204474A1/xx unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/ja active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX350418B (es) | 2017-09-06 |
| JP2018076360A (ja) | 2018-05-17 |
| CN104540831B (zh) | 2017-11-07 |
| EA201500050A1 (ru) | 2015-09-30 |
| US9580438B2 (en) | 2017-02-28 |
| MY167785A (en) | 2018-09-25 |
| CN104540831A (zh) | 2015-04-22 |
| EA029718B1 (ru) | 2018-05-31 |
| SG11201408617PA (en) | 2015-01-29 |
| EP2867237A1 (en) | 2015-05-06 |
| UA116541C2 (uk) | 2018-04-10 |
| BR112014032581A8 (pt) | 2018-08-14 |
| JP6272846B2 (ja) | 2018-01-31 |
| NZ702618A (en) | 2016-12-23 |
| MX2014015938A (es) | 2015-07-21 |
| WO2014001464A1 (en) | 2014-01-03 |
| CA2877589C (en) | 2019-11-26 |
| AU2013283318A1 (en) | 2015-01-22 |
| ZA201409194B (en) | 2017-08-30 |
| US20150158878A1 (en) | 2015-06-11 |
| AU2013283318B2 (en) | 2017-11-23 |
| IN2014MN02562A (ja) | 2015-07-24 |
| IL236463A0 (en) | 2015-02-26 |
| KR20150037877A (ko) | 2015-04-08 |
| AU2018201275A1 (en) | 2018-03-15 |
| BR112014032581A2 (pt) | 2017-06-27 |
| US20170240556A1 (en) | 2017-08-24 |
| CA2877589A1 (en) | 2014-01-03 |
| JP2015525742A (ja) | 2015-09-07 |
| KR102155559B1 (ko) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1204474A1 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
| IL243976B (en) | kdm1a inhibitors for disease treatment | |
| HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
| HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
| HK1221408A1 (zh) | 用於治療成膠質細胞瘤的組合療法 | |
| HK1199814A1 (en) | Inhibition of adaptor associated kinase for the treatment of pain | |
| SG10201912275YA (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders | |
| EP2911669A4 (en) | SYNERGISTIC COMBINATION OF IMMUNOLOGICAL INHIBITORS FOR THE TREATMENT OF CANCER | |
| HK1201755A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| EP2903619A4 (en) | PHOSPHODIESTERASE INHIBITORS FOR TREATING TASTE AND ODORAT DISORDERS | |
| HK1206721A1 (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23-- | |
| IL235127A (en) | Hpn-100 for use in the treatment of nitrogen-related diseases | |
| EP2825173A4 (en) | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISEASES AND RIBOSOMAPATHIES | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| IL237912B (en) | History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| EP2986301A4 (en) | PHOSPHODIESTERASE 5A INHIBITORS FOR THE TREATMENT OF MUSCLE DYSTROPHY | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer |